Thousand Oaks-based Amgen said Thursday that it has received U.S. Food and Drug Admnistration (FDA) approval on its denosumab treatment for reducing fractures and other bone problems in cancer patients. The new drug will be sold under the name XGEVA. The new drug is being used to prevent complications which happen when cancer spreads to the bones. The Amgen drug is also marketed for treating ostereoposis under the name Prolia.
Top NewsFriday, November 19, 2010
Amgen Gets FDA Approval On Bone Drug